CG Oncology, Inc.
Business
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy designed to treat bladder cancer by eliminating cancer cells directly and activating anti-tumor immune responses. The company is conducting Phase 3 trials (BOND-003 and PIVOT-006) evaluating cretostimogene monotherapy in high-risk and intermediate-risk non-muscle invasive bladder cancer patients, with a BLA submission initiated in late 2025 for its initial indication. Cretostimogene is administered intravesically, similar to standard BCG therapy, and the company is building commercial infrastructure to support potential U.S. market launch.
Summary from 10-K filed 2026-02-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total revenues | 4 | 1 | 204,000 | |
| Cost of sales | 5 | — | — | |
| Research and development | 117 | 82 | 46 | |
| General and administrative | 74 | 34 | 10 | |
| Total operating costs and expenses | 195 | 116 | 56 | |
| Loss from operations | −191 | −115 | −55 | |
| Interest income, net | 30 | 27 | 7 | |
| Other (expense) income, net | −152,000 | 3,000 | −62,000 | |
| Total other income, net | 30 | 27 | 7 | |
| Net loss and comprehensive loss | −161 | −88 | −49 | |
| Deemed dividend on redeemable convertible preferred stock issuances | 0 | 0 | −410,000 | |
| Cumulative redeemable convertible preferred stock dividends | 0 | 0 | −19 | |
| Net loss attributable to common stockholders | −161 | −88 | −68 | |
| Net loss per share , basic | −2.08 | −1.41 | −15.65 | |
| Net loss per share , diluted | −2.08 | −1.41 | −15.65 | |
| Weighted average shares of common stock outstanding, basic | 77 | 62 | 4 | |
| Weighted average shares of common stock outstanding, diluted | 77 | 62 | 4 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-07-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 32 | — | 257 | 8 | — | |
| Marketable securities | 710 | — | 485 | 179 | — | |
| Inventory | 2 | — | 0 | — | — | |
| Accounts receivable, net | 688,000 | — | 0 | — | — | |
| Prepaid expenses and other current assets | 15 | — | 12 | 6 | — | |
| Total current assets | 759 | — | 754 | 194 | — | |
| Property and equipment, net | 16 | — | 272,000 | 69,000 | — | |
| Operating lease right-of-use assets | 4 | — | 221,000 | 422,000 | — | |
| Intangible assets, net | 575,000 | — | 0 | — | — | |
| Goodwill | 10 | 10 | 0 | — | — | |
| Other assets | 2 | — | 94,000 | 19,000 | — | |
| Total assets | 792 | — | 755 | 199 | — | |
| Accounts payable | 6 | — | 7 | 3 | — | |
| Operating lease liabilities, current portion | 915,000 | — | 186,000 | 217,000 | — | |
| Accrued expenses and other current liabilities | 24 | — | 15 | 10 | — | |
| Total current liabilities | 31 | — | 21 | 14 | — | |
| Long-term debt | 3 | — | 0 | — | — | |
| Operating lease liabilities, net of current portion | 3 | — | 52,000 | 244,000 | — | |
| Deferred tax liability | 307,000 | — | 0 | — | — | |
| Other liabilities | 2 | — | 0 | — | — | |
| Total liabilities | 39 | — | 21 | 15 | — | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock, $0.0001 par value per share; 700,000,000 and 700,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 80,689,128 and 76,154,783 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 8,000 | — | 8,000 | — | — | |
| Additional paid-in capital | 1,132 | — | 951 | 7 | — | |
| Accumulated deficit | −379 | — | −218 | −130 | — | |
| Total stockholders' equity | 753 | — | 733 | −123 | −78 | |
| Total liabilities and stockholders' equity | 792 | — | 755 | 199 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net loss | −161 | −88 | −49 | |
| Depreciation and amortization | 1 | 32,000 | 17,000 | |
| Amortization of loan fees | — | — | 3,000 | |
| Final payment amortization and loss on debt extinguishment | — | — | 767,000 | |
| Success fee amortization | — | — | 37,000 | |
| Stock-based compensation expense | 27 | 11 | 2 | |
| Accretion of discount on short-term investments | −1 | −5 | −3 | |
| Non-cash interest expense (income) | −768,000 | — | — | |
| Non-cash lease expense | 34,000 | −22,000 | 12,000 | |
| Prepaid expenses and other current assets | −2 | −6 | −3 | |
| Accounts receivable, net | −320,000 | — | — | |
| Inventory | −444,000 | — | — | |
| Other assets | −2 | −75,000 | 13,000 | |
| Accounts payable | −2 | 3 | 2 | |
| Accrued expenses and other current liabilities | 9 | 5 | 4 | |
| Other liabilities | −487,000 | — | — | |
| Net cash used in operating activities | −132 | −79 | −46 | |
| Proceeds from sales and maturities of investments | 844 | 745 | 396 | |
| Purchases of investments | −1,068 | −1,046 | −518 | |
| Acquisition, net of cash acquired | −22 | — | — | |
| Purchases of property and equipment | −134,000 | −234,000 | — | |
| Net cash used in investing activities | −246 | −301 | −121 | |
| Proceeds from initial public offering, net of issuance costs | — | 406 | — | |
| Proceeds from follow-on public offerings, net of issuance costs | 147 | 223 | — | |
| Proceeds from issuance of Series F redeemable convertible preferred stock, net of issuance costs | — | — | 105 | |
| Payments of success fee or long-term debt | — | −365,000 | −16 | |
| Proceeds from exercise of common stock options | 6 | 3 | 2 | |
| Stock issuance costs | −316,000 | −3 | −3 | |
| Net cash provided by financing activities | 154 | 628 | 87 | |
| Net (decrease) increase in cash and cash equivalents | −225 | 249 | −80 | |
| Cash paid for interest | 103,000 | — | 376,000 | |
| Cash paid for taxes | 16,000 | — | — | |
| Reclassification of 38,413,909 redeemable convertible preferred stock to 38,413,909 shares of common stock | — | 308 | — | |
| Conversion of stock issuance costs | — | 7 | — | |
| Stock issuance costs, unpaid and accrued | 46,000 | — | 1 | |
| Operating lease right-of-use asset obtained in exchange for lease liabilities | 859,000 | 0 | 221,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CG Oncology, Inc.'s CIK number?
CG Oncology, Inc.'s SEC CIK number is 0001991792 (1991792). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CG Oncology, Inc.'s SEC filings?
All of CG Oncology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CG Oncology, Inc. last report earnings?
CG Oncology, Inc. (CGON) most recently filed an earnings 8-K with the SEC on May 8, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-213440). This is CG Oncology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is CG Oncology, Inc.'s most recent earnings 8-K?
CG Oncology, Inc.'s latest earnings 8-K (Item 2.02) was filed May 8, 2026 under accession 0001193125-26-213440. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CG Oncology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →